According to clinical observations and experimental reports, puerarin can dilate coronary arteries, lower blood pressure, slow down heart rate, and reduce myocardial oxygen consumption index without obvious negative inotropic effects; it can also reduce cholesterol and blood viscosity, Improve microcirculation and protect myocardium. Used for the treatment of myocardial infarction, angina pectoris, retinal arteriovenous occlusion, sudden deafness and raw materials for making injections and capsules.

Puerarin injection is currently widely used in clinical treatment of ischemic cardiovascular and cerebrovascular diseases. Because of the long course of clinical application, drug accumulation and toxicity are prone to occur. As the clinical application of puerarin injection continues to expand, reports of adverse reactions have also increased.

Suspected adverse reactions caused by this product mainly manifest as various types of allergic reactions, mainly drug fever, rash, allergic asthma, systemic allergic reactions including anaphylactic shock, etc. The incubation period for allergic reactions ranges from ten minutes to 13 days. Most of them occur during continuous medication and recover after discontinuation of medication and anti-allergic treatment. Puerarin injection can also cause hemolytic anemia. Patients experience low back pain, difficulty urinating, and hematuria. The symptoms are generally relieved after stopping the drug and receiving symptomatic drug treatment, but there are cases of death due to hemolytic anemia. In addition, this product can also cause liver and kidney damage. Patients may experience limb weakness, loss of appetite, jaundice, and significant increases in transaminases, blood potassium, and urea nitrogen. After symptomatic treatment, liver and kidney functions return to normal.

In view of the fact that intravenous infusion of puerarin injection may cause some adverse reactions, medical staff are reminded to strictly grasp the indications and strengthen clinical medication monitoring to prevent the occurrence of serious adverse reactions. For elderly and frail patients, attention should be paid to the monitoring of blood routine, liver and kidney functions, etc., and the course of treatment should not be too long.

It is worth noting that it is currently winter, and the number of patients with cardiovascular and cerebrovascular diseases is increasing day by day. Most patients voluntarily request infusions to prevent diseases. Therefore, patients must be persuaded to use oral preparations as much as possible. General practitioners should also pay attention to the recent increase in adverse reactions caused by infusions, such as allergies and hemolysis that damage liver and kidney function. There have been many reports, and everyone should be vigilant.